SavedAdd your journal

Journals / Meme Sağlığı Dergisi / 2006 / Cilt: 2 - Sayı: 3

Erken evre meme kanserinde in vitro bromodeoksirüdin işaretleme indeksinin (BRDU-İİ) standart prognostik ve predikdif faktörlerle kaeşılaştırılması

Ersin Selçuk ÜNAL
BEYZA ÖZÇINAR
Vahit ÖZMEN
Ayhan BİLİR
Abdullah İĞCİ
Mahmut MÜSLÜMANOĞLU
Mustafa KEÇER
Mesut PARLAK
Pages
118–121
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Our results suggest that the BrdU LI might be used as a prognostic marker to identify of patients at higher risk of relapse and to select the most appropriate adjuvant treatment for an individual patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT AIM: Various putative prognostic factors were studied in early breast cancer to evaluate local and systemic recurrence rates and make a decision for adjuvant treatments.
📊
Key Findings & Data:PATIENTS AND METHODS: After a staging work-up, the BrdU LI has been prospectively analysed in primary tumor fragments obtained from 81 consecutive patients with early breast cancer.
💡
Conclusion & Impact:CONCLUSION: Our results suggest that the BrdU LI might be used as a prognostic marker to identify of patients at higher risk of relapse and to select the most appropriate adjuvant treatment for an individual patient.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Meme neoplazmları · Bromodeoksirüdin · İmmünohistokimya

Abstract

ABSTRACT AIM: Various putative prognostic factors were studied in early breast cancer to evaluate local and systemic recurrence rates and make a decision for adjuvant treatments. In this study, the prognostic value of bromodeoxyuridine labeling index (BrdU LI) has been investigated in patients with early breast cancer and compared with other established clinical and biological factors. PATIENTS AND METHODS: After a staging work-up, the BrdU LI has been prospectively analysed in primary tumor fragments obtained from 81 consecutive patients with early breast cancer. RESULTS: The mean and median BrdU LI values for the whole group of patients were 6.22% and 5.18% (range: 0-27.33), respectively. Further analysis revealed that the BrdU LI rate was significantly higher in patients who had local recurrence (p= 0.026), or systemic metastases (p= 0.004). CONCLUSION: Our results suggest that the BrdU LI might be used as a prognostic marker to identify of patients at higher risk of relapse and to select the most appropriate adjuvant treatment for an individual patient.

Özet

AMAÇ: Erken evre meme kanserinde lokal ve sistemik nüks oranlarının ve tedavi seçeneklerinin belirlenmesi için değişik prognostik ve prediktif faktörler değerlendirilmiştir. Bu çalışmada amaç, Brdu-İİ’nin erken evre meme kanserinde prognostik değerini araştırmak ve bunu diğer klinik ve biyolojik olarak tespit edilmiş prognostik ve prediktif faktörlerle karşılaştırmaktır. MATERYAL VE METOD: Bu çalışmada, erken evre meme kanseri tanısı konulan, tedavi ve takip edilebilen 81 meme kanserli hastada Brdu-İİ saptanarak, bunun diğer prognostik/prediktif faktörlerle karşılaştırması yapılmıştır. BULGULAR: Hastalarda ortanca ve ortalama Brdu-İİ, %6,22 ve %5,18 olarak bulunmuştur. Yapılan istatistiksel analizde; lokal (p=0,026) ve sistemik nüks (p=0,004) saptanan hastalarda Brdu-İİ’nin anlamlı olarak yüksek olduğunu gösterilmiştir. SONUÇ: Erken evre meme kanseri tanısı konulup, yüksek Brdu-İİ saptanan hastalarda lokal nüksün daha fazla olduğunu ve adjuvan tedavi seçiminde Brdu-İİ’nin prognostik bir faktör olarak kullanılabileceğini söyleyebiliri

🔖

Cite This Article

ÜNAL, E. S., ÖZÇINAR, B., ÖZMEN, V., BİLİR, A., İĞCİ, A., MÜSLÜMANOĞLU, M., KEÇER, M., PARLAK, M. (2006). Erken evre meme kanserinde in vitro bromodeoksirüdin işaretleme indeksinin (BRDU-İİ) standart prognostik ve predikdif faktörlerle kaeşılaştırılması. Meme Sağlığı Dergisi, Cilt: 2 - Sayı: 3, 118–121. https://ajindex.com/articles/278307

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ünal M. Meme Hastalıklarına giriş ve tarihçe. Genel Cerrahi Cilt-1, Nobel Tıp Kitabevleri. 2002; 41:533-536
  2. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. Cancer 1990; 65:1194-1205
  3. Clark GM. Prognostic factors: Is there a real progress? In: The Secvond European Congress on Senology Congress Book, 1994; 77-82
  4. Waldman FM, Chew K, Ljung BM, Goodson W, Hom J, Duarte LA, Smith HS, Mayall B. A comparison between bromodeoxyuridine and H³ thymidine labeling in human breast tumors. Modern Patol 1991; 4:718-722
  5. Bilir A, Ozmen V, Kecer M, Eralp Y, Cabioglu N, Ahishali B, Camlica H, Aydiner A. Thymidine labeling index: prognostic role in breast cancer. Am J Clin Oncol. 2004; 27:400-6
  6. Spratt JS, Donegan WL, Sigdestad CP. Epidemiology and etiology. In Donegan WL, Spratt JS (eds). Cancer of the Breast. Philadelphia, WB Saunders Co, 1995; 356-377
  7. Meyers JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994; 74:2287-2289
  8. Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation and its relation to clinical features and relapse in breast cancer. Cancer 1981; 48:974-979
  9. Rew DA, Campbell ID, Taylor I, Wilson GD. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2’deoxyuridine labeling: a flow cytometric study of 75 tumors. Br J Surg 1992; 79:335-339
  10. Berg JW, Robbins GF. Factors influencing short and long term survival of breast cancer patients. Surg Gynecol Obstet 1996; 122:1311-1316
  11. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Paus M, Deytieux S, Le Doussal V, Tubiana- Hulin M, Brunet M. Multiparemetric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84:1266-1272
  12. Beerman H, Kluin M, Hermans J, van de Velde CJH, Cornelisse CJ. Prognostic significance of DNA ploidy in a series of 690 primary breat cancer patients. Int J Cancer 1990; 45:34-39
  13. Winters Z, Mohube P, Gray C, Wright C, Teare J, Lange M, Manell A, Myburgh JA. Tumors kinetics in breast cancer. South African Journal of Surgery 1994; 32:135-140
  14. Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello O, Bonetti F, Nortilli R, turazza M, Cetto GL. Tumor proliferative activity and response to first line chemothrapy in advanced breast carcinoma. Breast Cancer Research and Treatment 1996; 38:289-297
  15. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre J